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Over the last two decades exciting advances have been made in the understanding of the
immune response to cancer. These are likely to impinge on the development of novel, log-
ical strategies for cancer therapy. Antibodies, vaccines and immune effector agents are
likely to be routinely used for the management of patients with solid tumours within the
next decade.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Although tumour immunology has been the subject of re-
search and clinical investigation for several decades, there
has undoubtedly been a resurgence of interest within recent
years in the immune response to cancer, not only as a basis
for new therapies, but also as a critical element in realising
the immense promise of modern anticancer drug develop-
ment, which has been focused particularly on targeted ther-
apy with small molecules.
Viewed from a certain perspective, the future for cancer
therapy appears very bright indeed. The armamentarium
looks set to expand at an unprecedented rate over the next
5 years, as a wide range of small molecules currently in devel-
opment is introduced into clinical practice (Fig. 1). The reality
could be rather different, however, since the hurdles in taking
a drug to the clinic can be substantial, and much depends on
whether society will be willing to meet the cost, a question
that will depend in turn on how effective the new drugs turn
out to be.
In practice cancer drug development will need to be prior-
itised at a relatively early stage if drug developers are to man-
age the difficult balance between investment and return and
to introduce effective treatments that health providers will
consider economic. How can such prioritisation be achieved?er Ltd. All rights reservedHow will diagnostics services be provided to identify patients
likely to respond to targeted therapy? Can valid surrogate
endpoints be established in cancer to make novel drug devel-
opment sufficiently cost effective? Can we use healthy volun-
teers in first to man studies of cancer drugs? Immunology can
provide an answer to many of these questions.
2. Immunology in drug development
There are essentially only four approaches for industry to pur-
sue in developing novel therapies for cancer: small molecules,
monoclonal antibodies, gene therapy, and vaccines (Fig. 2). In
recent years, the energy of industry has been concentrated on
developing small molecules, but since the introduction of
trastuzmab in 1999, and later of rituximab and bevacizumab,
monoclonal antibodies have been a resounding and surpris-
ing success. As a result, drug developers are looking much
more closely at tumour immunology in all its aspects, to
investigate whether in its broad sense it can help in the devel-
opment of small molecules and be combined with small mol-
ecules in the adjuvant setting, which is clearly the direction in
which molecular therapies are headed.
The way clinical research and development is organised is
going to be heavily dependent on immunology as an analyti-
cal tool in the coming years. Drug developers are going to be
unwilling in the future to pursue clinical trials unless a bio-.
Fig. 1 – A considerable number and variety of novel therapies for cancer are potentially going to become available within the
next few years, as illustrated by these data on predicted approval dates (New Drug Applications; NDAs) for new cancer
therapies in the USA. Reprinted with permission from Ref. [2].
Fig. 2 – New therapeutic strategies in oncology include targeting cell signalling pathways implicated in tumour differentiation
and growth, through small molecule tyrosine kinase inhibitors, and monoclonal antibodies. PKC, protein kinase C; VEGF,
vascular endothelial growth factor.
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the role of cholesterol as a biomarker for the efficacy of stat-
ins in reducing cardiovascular risk.1
Although at present no such markers exist for cancer,
immunological techniques can almost certainly be used to
provide them. They will enable the development of a clinical
assay based on a drug’s molecular target, which could be used
to look for molecular signatures of response in different sub-
sets of patients, and for markers of downstream biochemical
changes. Such clinical assays would mean that rather than
concentrating on toxicity, Phase I clinical trials could be used
to determine maximal effective dose,2 so streamlining the
discovery process.
Another development I consider likely will be the need for
a surrogate for short-term responses in Phase III clinical tri-
als, in order to allow patients who fail to respond to be discon-
tinued from the trial, again helping to streamline andmanage
the costs and practical challenges of drug development, aswell as allowing non-responders to be identified early and
so be in a position to receive an alternative treatment.
The importance of biomarkers and surrogates in modern
cancer drug development was powerfully illustrated in the
case of the tyrosine kinase inhibitor, gefitinib. Clinical trials
in small numbers of patients withmetastatic lung cancer sug-
gested a dramatic response to treatment.3,4 Subsequent Phase
III trials, however, failed to demonstrate any difference be-
tween gefitinib and best available chemotherapy.5 This was
obviously a tremendous disappointment for patients with
lung cancer, and it also raised serious issues for the develop-
ment of new drugs, which is driven by commercial impera-
tives as well as by scientific aspirations, and which
therefore depends on a certain degree of predictability.
Not surprisingly, experiences such as that with gefitinib
have led to strenuous efforts to incorporate techniques into
drug development that can help to segregate responders from
non-responders in advance of large clinical trials. And it is
Fig. 3 – The combined analysis of NCCTG-N9831/NSABP-B-
31 demonstrated that the addition of trastuzumab to AC
paclitaxel significantly improved disease-free survival (a)
and overall survival (b) in women with HER2-positive breast
cancer. (A, doxorubicin; C, cyclophosphamide; T, paclitaxel;
H, trastuzumab).
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Automated, quantitative immunohistochemistry based on
sophisticated tissue analysis now enables individual response
to be assessed objectively and reproducibly, avoiding the prac-
tical limitations of relying on histopathologists, who are often
in short supply.
3. Immunology and cancer therapy
Immunotherapy for cancer is developing through a range of
approaches, including targeting with monoclonal antibodies,
either alone or coupled to a drug, toxin or radioisotope, the
use of recombinant cytokines, and specific immunotherapy
through activated T cells.
As I mentioned above, one of the developments that has
placed immunology at the centre of clinical research in oncol-
ogy in recent years is the introduction of monoclonal antibod-
ies as targeted therapy. And if metastatic disease is the setting
in which these agents were first shown to be effective, it is in
adjuvant therapy that their benefits will be fully realised.
Based on the theoretical understanding of how these drugs
act, a monoclonal antibody would be expected to have a
much more marked effect in the adjuvant setting.
Recently the results from two large clinical trials compar-
ing adjuvant treatment for breast cancer with and without
trastuzumab have demonstrated that trastuzumab confers a
significant benefit in terms of disease-free and overall sur-
vival compared with chemotherapy alone (Fig. 3).6,7 These
are powerful data, and I would expect similarly dramatic re-
sults to be seen with adjuvant bevacizumab.
Inducing a T cell-mediated response to a tumour-specific
antigen is now recognised as a rational approach to cancer
therapy, and a range of potential therapeutic target antigens
is being explored (Table 1). Advances in developing immuno-
therapy via T cell activation are likely to arise from techniques
that can purify the peptide antigen and so standardize the
immunogen for use across the patient population. A diagnos-
tic assay could be used to determine whether an individual’s
tumour did indeed express the antigen, and thereforewhether
that patient would be likely to respond. Antigen presentation
is a critical factor in immunization, and this can be enhanced
by the use of dendritic cell precursors, which are isolated from
the individual and allowed to take up antigen before being
incubated and then infused back into the patient, where theyTable 1 – Potential therapeutic target antigens
Differentiation antigens Shared self-antigens
Tyrosinase MAGE 1
CEA MAGE 3
Ig idiotype BAGE
GP100 RAGE
GP75 MUC 1
TRP2 NY-ESO1
PSA
BAGE, B melanoma antigens; CDK, cyclin-dependent kinase; CEA, carcino
1 protein; RAGE, receptor for advanced glycation end-products; PSA, prostcan generate a cytotoxic T cell response directed at the anti-
gen and hence at the tumour.
3.1. Immunology and cancer prevention
Another area in which immunology is likely to play an
increasingly important role is cancer prevention in individu-
als considered to be at increased risk for disease. There is cur-
rently intense interest in identifying genetic polymorphismsMutated self-antigens Overexpressed oncopeptides
CDK4 HER2/Neu
BCatenin P53/WT
P53
Ras
Bcr-abl
embryonic antigen; MAGE, melanoma antigen; MUC1, human mucin
ate-specific antigen; TRP, tyrosinase-related protein-2; WT, wild type.
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such as BRCA1, BRCA2 and APC (adenomatous polyposis coli),
which are associated with a markedly increased risk for can-
cer, but those in low penetrance susceptibility genes, which
are associated with a less marked increase in cancer risk on
their own but which when pooled together can indicate
groups of people in which cancer incidence is likely to be
high. Over the next decade, molecular epidemiology will en-
able genetic and environmental factors to be clearly related
to one another, allowing individual risk to be identified more
precisely. While we already havemarkers of cancer risk, these
are not molecular but histopathologic. So for example there is
prostatic intraepithelial neoplasia, hyperplasias in the breast,
dysplasias in the lung, adenomas in the colon, and so on.
These are not good markers for drug development because
they require biopsies and subjective assessment by a pathol-
ogist, rather than objective scoring of a biochemical or molec-
ular factors. So I think we are going to see a huge level of
interest in this area with immunology playing a large part in
the diagnostics.
4. Summary
There are a number of obstacles to overcome in harnessing
the immune response for use in cancer therapy. In the immu-
nological targeting of cancer the cost of development is a ma-
jor obstacle, especially if therapies have to be tailored to
individual patients. Another challenge is the lack of surrogate
endpoints for response. There are good surrogates in immu-
notherapy for immune stimulation, but correlating these to
outcomes in terms of clinical gain is difficult. We need better
immune adjuvants, particularly to obviate the need to work
with cells ex vivo, which currently adds to the complexity
and the cost of treatment. And then there is the sheer com-
plexity of cancer management resulting from aspects such
as immunosuppression, the generation of antigen loss vari-
ants, and the considerable heterogeneity of tumours between,and even within patients, which presents subtle molecular
and immunological differences that make a uniform ap-
proach very difficult.
Despite these challenges I believe that over the next dec-
ade, immunology is going to play a prominent part in the ef-
fort to reduce the burden of malignant disease, not just as a
basis for new therapies exploiting the immune response,
but also as a means of addressing some of the challenges
inherent in introducing molecular targeted small molecules
and in new approaches to classical chemotherapy.R E F E R E N C E S1. Chasman DI, Posada D, Subrahmanyan L, et al.
Pharmacogenetic study of statin therapy and cholesterol
reduction. JAMA 2004;291(23):2821–7.
2. Sikora K. Surrogate endpoints in cancer drug development.
Drug Discov Today 2002;7(18):951–6.
3. Fukuoka M, Yano S, Giaccone G, et al. Final results from a
phase II trial of ZD1839 (‘Iressa’) for patients with advanced
non-small-cell lung cancer (IDEAL 1). In: 2002 ASCO annual
meeting; 2002.
4. Kris G, Natale RB, Herbst RS, et al. A phase II trial of
ZD1839 (‘Iressa’) in advanced non-small cell lung cancer
(NSCLC) patients who had failed platinum- and
docetaxel-based regimens (IDEAL 2). In: 2002 ASCO annual
meeting; 2002.
5. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in
combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin
Oncol 2004;22(5):777–84.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med 2005;353(16):1659–72.
7. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast
cancer. N Engl J Med 2005;353(16):1673–84.
